^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    COMPANY:
    Salignostics

    i
    Other names: Saliva Diagnostics | Salignostics
    Evidence

    News

    10ms
    Inocras unveils new MRDVision™ data, demonstrating industry-leading sensitivity in Head-to-Head clinical study against leading MRD NGS assay (Businesswire)
    "Today, Inocras...announced MRDVision, its solution for minimal residual disease (MRD) detection, validated to CLIA standards. The assay, previously available for research use only, is now ready for use in clinical settings, redefining the standard in MRD testing by enabling ultra-sensitive detection of circulating tumor DNA (ctDNA) with a simulated limit of detection (LOD) as low as 1 part per million (ppm)...Developed through the integration of Inocras’s comprehensive CancerVision™ WGS cancer profiling platform and Ultima Genomics’ ppmSeq™ technology, MRDVision delivers a breakthrough approach for tracking cancer recurrence and treatment response with unmatched accuracy, efficiency, and cost-effectiveness."
    Minimal residual disease • Clinical data
    |
    CancerVision
    over1year
    Salignostics, Sheba Medical Center Partner on saliva-based oral cancer test (Genomeweb)
    "Israeli diagnostics firm Salignostics said...that it has partnered with Sheba Medical Center to develop a saliva-based test for oral cavity cancer...Under the terms of the deal, Salignostics will work with ARC Innovation, the technology development arm of Tel Aviv, Israel-based Sheba, to develop a proof-of-concept test that uses genomic, proteomic, and extracellular biomarkers in saliva to detect tumors in the mouth."
    Licensing / partnership